Pfizer mulling over COVID-19 R&D pact with BioNTech: report

Coronavirus
(Getty)

Big Pharma Pfizer is mulling over a pact with partner BioNTech to develop a vaccine for COVID-19.

This is according to an interview from the U.S. giant’s Chief Scientific Officer Mikael Dolsten, who told Reuters it could work with the mRNA biotech to develop a vaccine, potentially more quickly than other routes, to combat the disease that is spreading quickly around the globe.

Dolsten, who met with President Donald Trump this week with other Big Pharma heads to talk about industry response to the virus, told the news wire: “We will share some of our thoughts with BioNTech also on what they do on COVID-19 and evaluate whether there are things that could merit to do together.”

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

BioNTech, which is looking to rival Moderna with its mRNA platform (Moderna is also speeding along the COVID-19 vaccine development route), has already said it’s looking to follow suit in creating an inoculation.  

Pfizer and the European biotech have a deal dating back to 2018 using mRNA tech for flu vaccines, but this could now be expanded for the novel coronavirus fight.

RELATED: Pfizer pays BioNTech $120M upfront to form mRNA flu vaccine pact

It would be joining a host of other pharmas, including Johnson & Johnson and Sanofi, that are teaming up to try to create a vaccine.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.